Storia in 4 fonti

Shionogi wins US approval for first pill to prevent Covid following exposure

Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in contact with an infected individual.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 mesi fa

Shionogi wins US approval for first pill to prevent Covid following exposure

Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in contact with an infected individual.

originale

Timeline cronologica

lunedì 1 giugno 2026·healio.com
FDA approves Xocova for COVID-19 prevention after exposure
The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to someone with the disease, according to the drug’s…
lunedì 1 giugno 2026·medpagetoday.com
FDA Approves Oral Antiviral to Prevent COVID-19 After Exposure
Ensitrelvir cut household contacts' risk of developing COVID by more than half

Shionogi wins US approval for first pill to prevent Covid following exposure

Confronto fonti

Shionogi wins US approval for first pill to prevent Covid following exposure

Timeline cronologica

FDA approves Xocova for COVID-19 prevention after exposure

FDA Approves Oral Antiviral to Prevent COVID-19 After Exposure

FDA approves Xocova for COVID-19 prevention after exposure

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative

FDA Approves Oral Antiviral to Prevent COVID-19 After Exposure

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative

Shionogi wins US approval for first pill to prevent Covid following exposure